IQVIA IPO
IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company helps pharmaceutical, biotech, and medical device companies accelerate drug development, optimize commercial strategies, and improve patient outcomes through data-driven insights. Investors view IQVIA as a critical partner to the pharmaceutical industry with exposure to growing healthcare data analytics and clinical research markets.
Key Facts
| Industry | Healthcare Technology |
| Founded | 2016 |
| Headquarters | Durham, NC |
| Employees | ~87,000 |
| Website | iqvia.com |
| Funding | Public company (NYSE: IQV) via spinoff and merger |
About IQVIA
IQVIA is a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company was formed through the merger of IMS Health and Quintiles, combining one of the world's largest healthcare data companies with a major clinical research organization. IQVIA leverages its vast repository of healthcare data, covering over 1 billion patient records globally, to provide insights that help pharmaceutical and biotech companies develop drugs more efficiently, understand market dynamics, and improve patient outcomes.
The company's integrated platform spans the entire drug development lifecycle, from early-stage research and clinical trials to commercialization and post-market surveillance. IQVIA's technology solutions include real-world evidence platforms, clinical trial optimization tools, and commercial analytics that enable life sciences companies to make data-driven decisions. As the healthcare industry increasingly embraces digital transformation and evidence-based medicine, IQVIA's unique combination of data assets, technology capabilities, and domain expertise positions it as an essential partner for pharmaceutical innovation and healthcare improvement initiatives worldwide.
IPO Status
IQVIA went public on NASDAQ in October 2017 following its formation from the merger of Quintiles and IMS Health. The company trades under the ticker symbol IQV and raised capital through its IPO to support its integrated approach to clinical research and healthcare data analytics. The merger created one of the largest contract research organizations in the world. Since going public, IQVIA has maintained its position as a leader in clinical research services and healthcare analytics. The company has benefited from increased outsourcing by pharmaceutical companies and growing demand for real-world evidence and data analytics in drug development. IQVIA has continued to make strategic acquisitions and investments to expand its capabilities and global reach.
Competitors
Frequently Asked Questions
Does IQVIA have a stock?
Yes, IQVIA completed its IPO in October 2017 on NASDAQ. The company went public following the merger of Quintiles and IMS Health, creating a leading life sciences services company.
When is the IQVIA IPO date?
IQVIA is already public, having completed its IPO in 2017. There is no upcoming IPO date as the company has been trading on NASDAQ for several years.
How can I buy IQVIA stock?
You can buy IQVIA stock through any licensed brokerage account using the ticker symbol IQV on NASDAQ. The stock is widely available through online brokers and trading platforms.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts